**MINUTES**

**CPIC CONFERENCE CALL**

DATE: May 1, 2014

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Update on CPIC guidelines in progress | - *CFTR*/ivacaftor: published on-line (http://www.pharmgkb.org/guideline/PA166114461)- *G6PD/*rasburicase guideline: accepted*- CYP2C9*/ *HLA-B*/phenytoin: See below- *CYP2D6*/SSRI: Evidence review complete; finalizing recommendation- *CYP3A5*/tacrolimus: Evidence review underwayGuideline Updates:- *HLA-B*/abacavir: published on-line (http://www.pharmgkb.org/guideline/PA166104997)- *SLCO1B1*/simvastatin: in revision- *CYP2C9*/*VCORC1*/warfarin: Will be a major update. Evidence review underway.- *HLA-B*/allopurinol: Will start mid-summer. Kelly will contact authors. | Kelly will follow-up on progress. |
| *CYP2C9*/*HLA-B*/Phenytoin guideline | Kelly presented guideline, specifically Table 1, Table 2 and the implementation tables in the supplement. CPIC members provided feedback and suggested adding a table that would combine both *CYP2C9* and *HLA-B* recommendations (instead of two separate recommendations). Plan to submit this guideline to *CPT* in late May. Will circulate the guideline to CPIC members for review and feedback. | Kelly will circulate final guideline draft to CPIC members for comments/edits. Please send all guideline comments/edits to Kelly.caudle@stjude.org by May 23rd. |
| CPIC gene/drug pair list on PharmGKB | The gene/drug pairs of interest list (discussed on previous CPIC calls) is now available on PharmGKB (<http://www.pharmgkb.org/cpic/pairs>). The list contains information and links to the CPIC guideline (if available), CPIC level (A, B, C or D), PharmGKB level of evidence, and pharmacogenetic information in the FDA labeling (if available). Links are also provided to information regarding the process used for prioritizing these gene/drug pairs, a legend for the different CPIC levels, and a downloadable table in excel format.  | Kelly and PharmGKB will continue to maintain and update this list.  |
| New gene-drug pair  | The CPIC Steering Committee approved the request to start the *CYP2C19*/voriconazole guideline. Kelly is organizing the author list and will coordinate the writing of this guideline. | Kelly will follow-up on progress. |
| Request to work with ACMG on pharmacogenes | In 2013, the ACMG published a policy statement on the disclosure of incidental findings from exome and genome sequencing and recommend that laboratories performing clinical sequencing seek and report variants for a defined list of genes. However, the list largely excludes pharmacogenes. ACMG has also created a working group to discuss recommendations for additional “incidental” genomic variants of clinical significance. Mary shared a letter sent from CPIC leadership to ACMG leadership encouraging ACMG to consider recommendations of use of pharmacogenetic information and offering our input on pharmacogenes to the ACMG working group. (Shortly after the CPIC conference call we received an email from ACMG leadership indicating an interest in CPIC involvement in the working group.) | Mary will follow-up. |
| Posting/sharing CPIC presentation slides on PharmGKB/CPIC site | Discussed posting/sharing CPIC-related presentation slides used by CPIC members. Discussed two ways of posting/sharing slides: 1) members could share their CPIC-related presentation slides on the CPIC working group site and 2) PharmGKB would post one to two standardized sets of slides publically that would be maintained by CPIC leadership/PharmGKB and members would be encouraged to use these slides when presenting about CPIC (e.g., a limited number of slides would be kept up to date)  | PharmGKB/Teri will follow-up. |
| Medicare Local Coverage determinations | Sam Johnson sent an email to CPIC members (dated April 28th, 2014) asking if any CPIC members or other interested parties have a desire to independently participate in an effort to catalog existing payment models (both CMS and commercial insurers) and possibly advocate for coverage for clinical pharmacogenetic testing. It was reiterated that CPIC is committed to development of guidelines to help clinicians understand HOW available genetic test results should be used to optimize drug therapy, rather than WHETHER tests should be ordered and so CPIC itself does not want to officially advocate for third party payment.  | If you are interested, please email Sam Johnson (samuel.g.johnson@kp.org). Sam will schedule a conference call for those interested. |
| CPIC Informatics working group update | -Working group in the process of determining the best approach to standardize functional status terms used to describe allelic variants across CPIC guidelines.- Kelly and Michelle developed implementation figures/tables for the *CYP2C9*/*HLA-B*-phenytoin guideline and these were presented (see above).-Michelle is creating a CPIC informatics working group webpage (available from the CPIC page on PharmGKB) that will describe the goal and focus of the working group as well as any other important information about this group (e.g., list of members, leaders, resources, etc.)-Informatics working group continues to work on translation tables for upcoming guidelines and guideline updates. | James, Michelle, and Bob will continue to update CPIC group on progress. |